Neoplasms

All Conditions

Digestive System Diseases

Gland and Hormone Related Diseases

Heart and Blood Diseases

Rare Diseases

Adenocarcinoma

Pancreatic Neoplasms

Thromboembolism

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Pancreatic Cancer

Antineoplastic Agents

All Drugs and Chemicals

Anticoagulants

Gemcitabine

Paclitaxel

Albumin-Bound Paclitaxel

Rivaroxaban

Tubulin Modulators

Antimitotic Agents

Antimetabolites

Patients without a prior TE will be treated with prophylactic dose and schedule of rivaroxaban (10 mg QD), together with standard dose and schedule of gemcitabine, nab-paclitaxel and PEGPH20.

Patients with a prior TE will be treated with therapeutic dose and schedule of rivaroxaban (15 mg BID for 21 days for induction if indicated, then 20 mg QD for chronic treatment), together with standard dose and schedule of gemcitabine, nab-paclitaxel and PEGPH20.

Nab-paclitaxel

PEGPH20

Kenneth Yu, MD, MSc

The purpose of this study is to test any good and bad effects of the study drug called PEGPH20. PEGPH20 alone is considered investigational. The Food and Drug Administration (FDA) has not approved the marketing or sale of PEGPH20, but have authorized its use in research studies with humans. PEGPH20 could shrink the cancer but it also can cause side effects. PEGPH20 is an enzyme that breaks down a specific tissue component called hyaluronan produced by some tumors. Pancreatic tumors often have a large amount of hyaluronan. The removal of hyaluronan from tumors may decrease tumor growth.

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

Pilot Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

This includes any grade 2 or grade 3 thromboembolic event as defined by NCI CTCAE v4.0 found on incidental imaging, which would indicate a need for medical intervention.

Halozyme Therapeutics

Miami Cancer Institute

Memorial Sloan Kettering Cancer Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma	NCT02921022	Pancreatic Canc... Advanced Pancre...	Gemcitabine Nab-paclitaxel PEGPH20	18 Years -	Memorial Sloan Kettering Cancer Center
Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma	NCT02921022	Pancreatic Canc... Advanced Pancre...	Gemcitabine Nab-paclitaxel PEGPH20	18 Years -	Memorial Sloan Kettering Cancer Center

Spots Global Cancer Trial Database for thromboembolic event (te)